# A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease

> **NCT01503736** · PHASE3 · COMPLETED · sponsor: **Panion & BF Biotech Inc.** · enrollment: 183 (actual)

## Conditions studied

- Hyperphosphatemia
- End Stage Renal Disease
- ESRD

## Interventions

- **DRUG:** ferric citrate
- **DRUG:** ferric citrate
- **DRUG:** ferric citrate

## Key facts

- **NCT ID:** NCT01503736
- **Lead sponsor:** Panion & BF Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-06
- **Final completion:** —
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01503736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01503736, "A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01503736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*